The clinicaltrials.gov site still shows that we are not yet recruiting, which probably explains why we have not heard about a first patient being dosed. We are now into Q2 and we are still waiting to hear about the approval to start the Russian part of the trial. It seems that we are starting to fall behind our plan. While this is not unusual where clinical trials are concerned, it may complicate the matter of capital rising and the timing of the announcement.
Maybe we will get some indication of where these matters are at in the quarterly report, which is due some time in the next eleven days?
Add to My Watchlist
What is My Watchlist?
